Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease
| Autor: | Anneli Verstraete, K Cheyns, Roger Bouillon, Paul Rutgeerts, Isolde Aerden, G. D'Haens |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Budesonide
medicine.medical_specialty Crohn's disease Hepatology biology business.industry medicine.drug_class Gastroenterology medicine.disease Bone remodeling Endocrinology Methylprednisolone Oral administration Prednisone Internal medicine medicine Osteocalcin biology.protein Corticosteroid Pharmacology (medical) business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 12:419-424 |
| ISSN: | 0269-2813 |
| Popis: | Background: Glucocorticosteroids are used frequently for the treatment of relapses of Crohn’s disease. Aim: To investigate the influence of the new topically active glucocorticosteroid budesonide in comparison with methylprednisolone on bone turnover in a randomized open trial. Methods: Twenty-nine patients received either budesonide (controlled ileal release formulation) 9 mg for 10 weeks, or methylprednisolone 32 mg (equivalent to 40 mg prednisone) orally for 3 weeks with subsequent tapering. Results: Patients who completed the trial with methylprednisolone (n = 8) had suppression of serum osteocalcin (30.2 ± 2.6 to 20.4 ± 2.0 ng/mL, P < 0.01), whereas no changes in this parameter of bone synthesis were observed during budesonide treatment (n = 11) (34.8 ± 3.1 to 33.0 ± 3.5 ng/mL). Urinary pyridinolines and deoxypyridinolines, highly sensitive markers of bone degradation, did not change in either group. Conclusion: Short-term methylprednisolone therapy impairs osteoblast activity in patients with Crohn’s disease whereas budesonide does not. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |